IBRX – immunitybio, inc. (US:NASDAQ)
Stock Stats
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
ImmunityBio (NASDAQ:IBRX) had its price target raised by analysts at HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month [Yahoo! Finance]
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
Form 8-K ImmunityBio, Inc. For: Jan 23
Form 4 ImmunityBio, Inc. For: Jan 20 Filed by: Simon Barry J.
Form 4 ImmunityBio, Inc. For: Jan 16 Filed by: Selecky Christobel
Form 144 ImmunityBio, Inc. Filed by: Selecky Christobel
Form 144 ImmunityBio, Inc. Filed by: Simon Barry J.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.